Thermo Fisher Scientific to Divest Microbiology Unit to Astorg for ~$1.08B

Shots: Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for ~$1.075B, incl. cash & a $50M seller note, as part of its portfolio optimization strategy The divested unit, which offers antimicrobial susceptibility testing and culture media solutions, generated $645M in revenue in 2025 and operates within Thermo Fisher’s Specialty Diagnostics segment…

ByRidhi Rastogi3 days ago

NEWS

CareDx to Divest Lab Products Unit to EuroBio Scientific for $170M

Shots: CareDx has entered a definitive agreement to divest its Lab Products business, incl. PCR & NGS-based transplant diagnostics, to EuroBio Scientific for $170M in cash Divestiture aims to streamline operations and refocus on core Precision Medicine Testing Services and digital solutions, while retaining exclusive North America rights to distribute post-transplant monitoring IVD tests, incl. AlloSeq…

ByRidhi RastogiApril 16, 2026

NEWS

Garda to Acquire Assertio for ~$125.1M Upfront

Shots: Garda Therapeutics has entered into a definitive agreement to acquire Assertio, delisting it from Nasdaq As per the deal, Garda will acquire Assertio for $18/share in cash (~$125.1M) plus a non-tradeable CVR related to potential future milestones for Sprix, with the deal expected to close in Q2’26 & remaining shares acquired later via a…

ByRidhi RastogiApril 9, 2026

NEWS

Lonza to Sell CHI Business to Lone Star Funds for ~$3B

Shots: Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceeds Lonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via…

ByRidhi RastogiMarch 9, 2026

NEWS

Novartis AG to Transfer Stake in Novartis India Limited to ChrysCapital

Shots: Novartis AG has signed an agreement with ChrysCapital to divest its 70.68% stake in Novartis India Limited (NIL), following a strategic review initiated in Feb 2024 The transaction, subject to customary closing conditions, is expected to close in Q3’26; the Board of NIL was formally notified post-signing Post-divestment, Novartis will further its transition into…

ByRidhi RastogiFebruary 20, 2026

Thermo Fisher Scientific to Divest Microbiology Unit to Astorg for ~$1.08B

CareDx to Divest Lab Products Unit to EuroBio Scientific for $170M

Garda to Acquire Assertio for ~$125.1M Upfront

Lonza to Sell CHI Business to Lone Star Funds for ~$3B

Novartis AG to Transfer Stake in Novartis India Limited to ChrysCapital

Contact US

FOLLOW US